Determining the Viability a Lozenge Dosage for Probiotics

May 19, 2026 updated by: Michael Glogauer, Ostia Sciences

A Short, Open, Phase 0 Study to Demonstrate the Viability of the Lozenge Dosage Form to Deliver SALI-10 Oral Probiotics

Gingivitis is an oral disease condition affecting 50% to 90% of adults globally. Gingivitis is a reversible inflammatory condition caused by the accumulation of dental plaque and the associated disruption of the host-microbial homeostasis. During gingivitis, the microbial community shifts from gram-positive health-associated bacteria, to gram-negative disease associated species. This shift triggers inflammatory responses, leading to tissue damage and, in some cases, progression to periodontitis.

A promising area of oral health is treating the oral cavity with gram-positive probiotics to improve oral health. One promising candidate is S. salivarius SALI-10. Typically oral probiotics are dosed to the oral cavity using lozenges. This study is a pre-clinical Phase 0 trial to determine is a lozenge is a viable dosage form for the delivery of salivarius SALI-10 oral probiotics.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Gingivitis is an oral disease condition affecting 50% to 90% of adults globally. The gingivitis pathology can be reversed by reduction or removal of microbial plaque that accumulates on hard and soft tissues and is considered standard of care in the industry. Regular oral hygiene in combination with therapeutics that delivers an anti-microbial benefit is thought to mitigate the onset of gingivitis. However, testing therapeutics for prophylaxis benefit to mitigate development of gingivitis has not been fully examined.

Neutrophils, a type of white blood cell (leukocyte), represent a key component of the innate defence system that protects periodontal tissue from both gingivitis and periodontitis. Not only are they the first line of cellular defence, but they are among the most abundant leukocytes within the periodontal tissues. For example, gingivitis is associated with a significant increase in the number of neutrophils that migrate to periodontal tissue. In contrast, individuals with too few neutrophils brought about by either congenital deficiencies in neutrophil numbers, or transit (LAD 1 and 2) or have an induced neutropenia by chemical induction with antimitotic agents such as cyclophosamide invariably develop periodontitis. Likewise, studies in KO mice that are defective in neutrophil transit also develop periodontitis. Consistent with the key contribution of neutrophils to both gingivitis and periodontitis, neutrophil transit to gingival tissue is highly regulated. The periodontium contains a highly orchestrated expression of select innate host defense mediators that facilitate the transit of neutrophils from the highly vascularized gingival tissue to the gingival crevice, where they form a "wall" between the host tissue and the dental plaque biofilm.

Gingivitis is a reversible inflammatory condition caused by the accumulation of dental plaque and the associated disruption of the host-microbial homeostasis. During gingivitis, the microbial community transitions from being dominated by gram-positive health-associated bacteria, such as Streptococcus species, to gram-negative periopathogens, including species of the genera Porphyromonas, Tannerella, Treponema and Prevotella. This dysbiotic shift triggers inflammatory responses, leading to tissue damage and, in some cases, progression to periodontitis.

A recent study on human experimental gingivitis identified three distinct host response phenotypes-high, low, and slow responders-based on clinical, inflammatory, and microbial parameters:

High Responders: Rapid plaque accumulation accompanied by a significant increase in gram-negative periopathogens and elevated inflammatory markers, such as interleukin-1β (IL-1β).

Low Responders: Similar plaque accumulation to high responders but lower inflammation, suggesting a more muted host response to bacterial dysbiosis.

Slow Responders: Delayed plaque accumulation and microbial succession, with prolonged dominance of health-associated Streptococcus species. This group exhibited delayed or reduced inflammation, demonstrating a more resilient microbial community and host response.

The microbial analysis revealed that the persistence of beneficial Streptococcus species, such as S. sanguinis and S. oralis, in slow and low responders correlates with a protective effect against the emergence of periopathogens and the associated inflammatory cascade. Conversely, the loss of these beneficial bacteria in high responders was linked to more severe inflammation, highlighting the critical role of the oral microbiome in modulating gingivitis severity.

Lantibiotic salivaricins are polycyclic peptides containing lanthionine and/or β-methyllanthionine residues that are produced by certain strains of Streptococcus salivarius, which almost exclusively reside in the human oral cavity. These molecules' importance stems from their antimicrobial activity towards relevant oral pathogens, which has been applied through the development of salivaricin-producing probiotic strains. However, salivaricins may also prove to be of great value in the development of new and novel antibacterial therapies in this era of emerging antibiotic resistance. In a study by Barbour & Philip 2014, they found that the bacteriocin, levan-sucrase production, and basic safety features of S. salivarius strains isolated from healthy Malaysian subjects demonstrated their potential for use as probiotics. A new bacteriocin production medium was developed with potential scale-up application for pharmaceuticals and probiotics from S. salivarius generating different lantibiotics. This is relevant for the clinical management of the oral cavity and upper respiratory tract in the human population. Appendix 1 includes a summary table that lists the relevant clinical trials that utilized S. salivarius.

Proposed Solution: S. salivarius SALI-10

It is proposed to use a novel strain, Streptococcus salivarius SALI-10, as a targeted microbial intervention to modulate the oral microbiome and prevent gingivitis. S. salivarius SALI-10 is hypothesized to:

  • Maintain a stable population of beneficial streptococci during plaque accumulation.
  • Inhibit the growth of periopathogens such as Porphyromonas, Tannerella, and Prevotella through competition and production of Salivaricin 10.
  • Delay or suppress the dysbiotic shift to gram-negative dominance, thereby reducing the inflammatory response.

By preserving microbial homeostasis, SALI-10 may emulate the microbial resilience observed in slow responders, offering a novel strategy for gingivitis prevention.

Before the therapeutic value of Streptococcus salivarius SALI-10 can be assessed, its dosage form must be validated. The classical method of delivering oral probiotics is in a lozenge form, having the individual suck on the lozenge until it dissolves. Once it is verified that this dosage form works for Streptococcus salivarius SALI-10, a full clinical trial to determine its therapeutic viability can be conducted.

2. STUDY OBJECTIVES

The aim of this study is to determine the short-term ability of the Streptococcus salivarius SALI-10 lozenges delivery system to modify the human oral microbiome composition and Oral Inflammatory Load (OIL). Specifically, the aim is to:

  • Assess the change in salivary levels of periodontal-disease-associated bacteria (e.g., P. gingivalis, T. forsythia, T. denticola, and P. micra).
  • Determine the change in beneficial bacteria levels (e.g., S. salivarius, S. parasanguinis).
  • Evaluate the change in Oral Inflammatory Load (OIL) by measuring oral neutrophil counts.

To monitor the short-term adherence of the 8-10 participants to the clinical protocol.

3. STUDY OVERVIEW

This study is designed as an open-label, single-arm, exploratory pilot study to be completed over 7 days with 8-10 participants. Participants will self-administer one lozenge containing S. salivarius SALI-10 (10 billion CFU/lozenge) each night after brushing and before bed. Participants will complete two (2) home sample kits, one before and one after the 7 days.

5. TEST PRODUCTS/INTERVENTIONS Each participant will receive seven (7) mint-flavoured SALI-10 lozenges. They will be instructed to take a lozenge daily after brushing by letting it dissolve in the mouth. The participants will be using the SALI-10 lozenges throughout the study. Each participant will also receive four (4) home-administered test kits: two (2) Saliva Collection Kits, and two (2) Saline Rinse Collection Kits.

5.2 Dispensing, Storage, and Accountability Once pre-screened, all participants will receive all study materials in the mail. This will include the seven (7) lozenges and the four (4) home-administered test kits: two (2) Saliva Collection Kits, and two (2) Saline Rinse Collection Kits. The subjects will follow provided instructions on when and how to brush their teeth. These instructions are explained in the procedure section.

The test kits are self-contained commercially available kits that include all instructions of use. Participants will be provided instructions on how to drop off the samples to Ostia Sciences Inc at 124 Edward St., Toronto, Suite 463, ON Canada M5G 1G6.

Participants will be instructed to discard all study materials at the end of the 7-day trial.

6. STUDY PROCEDURES

6.2 Product Dispensing and Use at Home The product will be mailed to the participant in a sealed box that will include instructions for at-home use and safety information, including emergency contact details. To monitor patient compliance, the clinical study manager will request an email confirmation at the end of the trial that all 7 lozenges were consumed. Subjects will be assigned a unique identification number in chronological order (e.g., from 1 to 10) as they enroll in the study. Subjects will be instructed to avoid using any other oral hygiene products. There will be no dietary restrictions during the study.

Subjects will be instructed to brush their teeth twice daily (morning and evening) for two minutes each time with a toothpaste and toothbrush and floss. The SALI-10 lozenges will be pre-packed when given to each participant.

6.3 Telephone Pre-Screening Potential study participants who contact the clinical trial coordinator for more information about the study via email will then be contacted via telephone. At this stage, the Recruitment Questionnaire will be completed to determine whether they are eligible for the screening phase of the study. If the subject is deemed eligible, they will be given the Informed Consent Form to read and ask any questions they may have and sign. The screening will be carried out until ten (10) subjects are enrolled.

There will be no in-person visits. Study participants will be mailed all study materials, which included the seven (7) lozenges, and the four (4) home-administered test kits: two (2) Saliva Collection Kits, and two (2) Saline Rinse Collection Kits. Subjects will also receive the study product for use at home with directions.

6.5 Day 0 (Baseline) Participants will utilize one (1) Saliva Collection Kit, and one (1) Saline Rinse Collection Kit. They will drop off the samples to Ostia Sciences as per the given instructions. After sample collection, participants will begin using the lozenges daily for 7 days. The participants will take one lozenge after brushing. They will allow the lozenges to dissolve without biting or swallowing and avoid eating and drinking for one hour. The participants will be instructed on proper oral hygiene and will be instructed to continue their home oral hygiene in addition to the use of their assigned product for 7 days (1 week). The participants will be instructed to discard the lozenges' container at the end of the study.

6.6 Day 7 (Completion) 24 hours after using the seventh (7th) lozenge, participants will utilize one (1) Saliva Collection Kit, and one (1) Saline Rinse Collection Kit. They will drop off the samples to Ostia Sciences as per the given instructions. Study participants will discard any remaining study materials they may have. Through email, the study manager will confirm adherence to protocol and provide post-study instructions. The subjects will be informed that this is the end of the study. They will be told that they may resume their regular oral hygiene. Afterwards, the investigators will ask the participants for their feedback in regards to their experience.

Study Type

Interventional

Enrollment (Actual)

8

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Toronto, Ontario, Canada, M5G 1G6
        • Ostia Sciences Inc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Male or female volunteers aged 18-70 years
  2. In good general health, ASA I
  3. Non-smokers
  4. Fluent in English

Exclusion Criteria:

  1. Presence of orthodontic bands.
  2. Presence of partial removal dentures.
  3. Dental pain at time of screening.
  4. History of allergy to a consumer or personal care products or dentifrice ingredients as determined by the dental profession monitoring the study.
  5. Participation in any other clinical study or test panel within one month before entering the study.
  6. Current use of anti-inflammatory, antibiotics, or antimicrobial drugs or within the last 30 days of enrolment.
  7. History of periodontal disease.
  8. History of systemic inflammatory or immune conditions
  9. Pregnant or nursing women.
  10. Use of tobacco products.
  11. Long-term antibiotic or anti-inflammatory therapy.
  12. Medical condition or any current usage of medication that the investigator considers may compromise the subject's safety as well as the quality of the study results;
  13. Use of any concomitant medication.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Receives Probiotic Lozenge

This study is an open-label, single-arm, exploratory pilot study to be completed over 7 days with 8-10 participants. Participants will self-administer one lozenge containing S. salivarius SALI-10 (10 billion CFU/lozenge) each night after brushing and before bed. Every participant will be given 7 SALI-10 lozenges.

  1. The aim of this study is to determine the short-term ability of the Streptococcus salivarius SALI-10 lozenges delivery system to modify the human oral microbiome composition and Oral Inflammatory Load (OIL). Specifically, the investigators aim to:

    • Assess the change in salivary levels of periodontal-disease-associated bacteria (e.g., P. gingivalis, T. forsythia, T. denticola, and P. micra).
    • Determine the change in beneficial bacteria levels (e.g., S. salivarius, S. parasanguinis).
    • Evaluate the change in Oral Inflammatory Load (OIL) by measuring oral neutrophil counts.
  2. To monitor the short-term adherence of the 8-10 participants to the clinical protocol.
Dietary supplement: Salivarius SALI-10
Lozenges containing live Streptococcus salivarius strain OSTIA SALI-10

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Oral Inflammatory Load (OIL)
Time Frame: Baseline (day 0) and day 7
Oral inflammatory load (OIL) is measured via oral neutrophil count in oral rinse samples (oPMN). Post-transplantation values (Day 7) are normalized to each participant's baseline (Day 0) value to evaluate the change in OIL. For normalization, each participant's baseline OIL was set to 1 by dividing the baseline neutrophil count by itself. Post-transplantation OIL values were then divided by the participants baseline to calculate fold change.
Baseline (day 0) and day 7
Change in SALI-10 Colonization Levels
Time Frame: Baseline (day 0) and day 7
Quantification of SALI-10 colonization using qPCR targeting the srnA2 gene. Samples were collected at baseline (Day 0) and post-transplantation (Day 7). The srnA2 gene encodes for phosphorylated lantibiotic synthesized by S.salivarius SALI-10
Baseline (day 0) and day 7
Changes in the Relative Abundance of P. Gingivalis
Time Frame: baseline (day 0) and day 7
Evaluation of pathogen suppression by quantifying the relative gene abundance of periodontal-disease-associated taxa (e.x. P. gingivalis, T. forsythia, P. micra and F. nucleatum) via qPCR. Relative gene abundance is expressed as the proportion of target bacterial 16s rRNA gene copies relative to the total bacterial 16s rRNA gene copies per mL. The measure reports the actual proportion at baseline and at day 7.
baseline (day 0) and day 7
Changes in the Relative Abundance of T. Forsythia
Time Frame: Baseline (day 0) and day 7
Evaluation of pathogen suppression by quantifying the relative gene abundance of periodontal-disease-associated taxa (e.x. P. gingivalis, T. forsythia, P. micra and F. nucleatum) via qPCR. Relative gene abundance is expressed as the proportion of target bacterial 16s rRNA gene copies relative to the total bacterial 16s rRNA gene copies per mL. The measure reports the actual proportion at baseline and at day 7.
Baseline (day 0) and day 7
Changes in the Relative Abundance of P. Micra
Time Frame: Baseline (day 0) and day 7
Evaluation of pathogen suppression by quantifying the relative gene abundance of periodontal-disease-associated taxa (e.x. P. gingivalis, T. forsythia, P. micra and F. nucleatum) via qPCR. Relative gene abundance is expressed as the proportion of target bacterial 16s rRNA gene copies relative to the total bacterial 16s rRNA gene copies per mL. The measure reports the actual proportion at baseline and at day 7.
Baseline (day 0) and day 7
Changes in the Relative Abundance of F. Nucleatum
Time Frame: Baseline (day 0) and day 7
Evaluation of pathogen suppression by quantifying the relative gene abundance of periodontal-disease-associated taxa (e.x. P. gingivalis, T. forsythia, P. micra and F. nucleatum) via qPCR. Relative gene abundance is expressed as the proportion of target bacterial 16s rRNA gene copies relative to the total bacterial 16s rRNA gene copies per mL. The measure reports the actual proportion at baseline and at day 7.
Baseline (day 0) and day 7

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oral Inflammatory Load
Time Frame: From enrollment to the end of treatment at 7 days.
Evaluate the change in Oral Inflammatory Load (OIL) by measuring oral neutrophil counts.
From enrollment to the end of treatment at 7 days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ostia Sciences

Investigators

  • Principal Investigator: Michael Glogauger, MD, Ostia Sciences Inc

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 6, 2025

Primary Completion (Actual)

June 15, 2025

Study Completion (Actual)

June 30, 2025

Study Registration Dates

First Submitted

February 4, 2025

First Submitted That Met QC Criteria

February 5, 2025

First Posted (Actual)

February 11, 2025

Study Record Updates

Last Update Posted (Actual)

June 16, 2026

Last Update Submitted That Met QC Criteria

May 19, 2026

Last Verified

February 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • OstiaPhase0_2025_02Feb_04

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

This is a Phase 0 trial, and no individual participant data will be kept.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe